A Phase II Study of agenT-797 (Invariant Natural Killer T Cells), Botensilimab, a Novel Fc-enhanced CTLA-4 Inhibitor, Plus Balstilimab (Anti-PD-1) With Ramucirumab and Paclitaxel for Patients With Previously Treated, Advanced Esophageal, Gastric, or Gastro-esophageal Junction Adenocarcinoma

Participants will receive study treatment with agenT-797, botensilimab, balstilimab, ramucirumab, and paclitaxel. When participants start each agent will depend on how their disease is affecting them.

开始日期2024-02-01

申办/合作机构

Memorial Sloan Kettering Cancer Center

NCT05108623 / Completed临床1期

A Phase 1, Open-Label Study of the Safety, Tolerability and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) as a Single Agent and in Combination With Approved Immune Checkpoint Inhibitors in Patients With Relapsed/ Refractory Solid Tumors

This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed/refractory (r/r) solid tumors, as well as define the recommended phase II dose in solid tumors. This Phase 1 study will also explore the safety, tolerability, and preliminary clinical activity of agenT-797 in combination with approved immune checkpoint inhibitors (ICIs), including pembrolizumab and nivolumab, in participants with r/r solid tumors.

开始日期2022-01-28

申办/合作机构

MiNK Therapeutics, Inc.

NCT04754100 / Completed临床1期

A Phase 1, Open-Label Study of the Safety, Tolerability, and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) in Subjects With Relapsed/Refractory Multiple Myeloma

开始日期2021-03-29

申办/合作机构

MiNK Therapeutics, Inc.

100 项与 AgenT-797 相关的临床结果

登录后查看更多信息

100 项与 AgenT-797 相关的转化医学

登录后查看更多信息

100 项与 AgenT-797 相关的专利（医药）

登录后查看更多信息

项与 AgenT-797 相关的文献（医药）

2023-02-15·Cancer research

Long-Chain Acylcarnitines Induce Senescence of Invariant Natural Killer T Cells in Hepatocellular Carcinoma

Article

作者: Cheng, Xue ; Zhang, Ziyao ; Weng, Xiufang ; Liang, Zhihui ; Wang, Wei ; Wu, Mi ; Wu, Xiongwen ; Li, Mingyu ; Chen, Yiqing ; Zhu, Peng ; Tan, Xiaosheng ; Zhu, Rongfei

Abstract:

CD1d-restricted invariant natural killer T (iNKT) cells actively patrol the liver and possess valuable antitumor potential. However, clinical trials evaluating administration of iNKT cell–specific agonist α-galactosylceramide (α-GalCer) have failed to achieve obvious tumor regression. Improving the efficacy of iNKT cell–based immunotherapy requires a better understanding of the factors restraining the clinical benefits. In the context of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), we found circulating and hepatic iNKT cells were hyperactivated but demonstrated imbalances in ratio and defective α-GalCer responsiveness. Exogenous IL2 helped to expand residual α-GalCer–responsive clones with reduced T-cell receptor diversity. However, transcriptome-wide analysis revealed activation of the senescence-associated secretory phenotype and dampened cytotoxicity in iNKT cells, weakening their immune surveillance capacity. The senescent status of iNKT cells from the patients was further illustrated by cell-cycle arrest, impaired telomere maintenance, perturbed calcium transport-related biological processes, and altered metabolism. Lipidomic profiling revealed the accumulation of long-chain acylcarnitines (LCAC) and aberrant lipid metabolism in HCC tissue. Exogenous LCACs, especially palmitoyl-carnitine and stearoyl-carnitine, inhibited iNKT cell expansion and promoted senescence. Collectively, our results provide deeper insights into iNKT cell dysregulation and identify a cell senescence–associated challenge for iNKT cell–based immunotherapy in HBV-related HCC. The mechanistic links between iNKT cell senescence and accumulated LCACs suggest new targets for anti-HCC immunotherapies.

Significance::

Patients with HBV-related HCC exhibit a cell senescence–associated dysregulation of invariant natural killer cells that is related to altered lipid metabolism and accumulated LCACs in tumor tissue.

2023-01-01·Journal of hepatocellular carcinoma

Efficacy of Invariant Natural Killer T Cell Infusion Plus Transarterial Embolization vs Transarterial Embolization Alone for Hepatocellular Carcinoma Patients: A Phase 2 Randomized Clinical Trial.

作者: Guo, Jia ; Liu, Fuquan ; Wu, Yifan ; Xiong, Fang ; Lu, Jun ; Guo, Jiang ; Bao, Xuli

Purpose:

Invariant NKT cells (iNKT) are CD1d-restricted T cells with the capacity of antitumor immunity. The safety of autologous iNKT cell treatment in hepatocellular carcinoma (HCC) has been verified. This study aimed to investigate its efficacy in advanced HCC after transarterial chemoembolization (TACE) failure.

Patients and methods:

This open-label, randomized, controlled, trial enrolled 60 patients with unresectable HCC after TACE failure at three centers. Transarterial embolization (TAE) was used instead of TACE to protect iNKT cell function. Patients were randomly assigned (1:1) to receive TAE therapy with (TAE-iNKT) or without (TAE) biweekly iNKT cell infusion. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), quality of life (QoL), peripheral blood cell count, and safety.

Results:

Fifty-four patients completed the study. Median PFS was significantly higher in TAE-iNKT patients (5.7 months [95% CI, 4.3-7.0 months]) compared with TAE patients (2.7 months [95% CI, 2.3-3.2 months]; hazard ratio 0.32 [95% CI, 0.16-0.63]; P<0.001). Higher ORR and DCR were observed in TAE-iNKT patients (52% and 85%, respectively) compared with TAE patients (11% and 33%; respectively). Five TAE-iNKT patients and 1 TAE patient achieved completed response. The median time to deterioration in QoL was longer in TAE-iNKT patients (9.2 months [95% CI, 6.0-13.3 months]) compared with TAE patients (3.0 months [95% CI, 2.9-3.0 months]). The mean lymphocytes were higher in the TAE-iNKT group than in the TAE group at 8 (1.48 vs 0.95×10⁹/L, P = 0.007) and 12 (1.49 vs 0.89×10⁹/L, P = 0.001) weeks. Grade 3 adverse events occurred in 1 TAE-iNKT patient (4%) and 5 TAE patients (19%). All the other adverse events were grade 1-2.

Conclusion:

iNKT cell infusion significantly improved PFS, ORR, DCR, and QoL with manageable toxicity during TAE therapy in patients with HCC. Trial Registration ClinicalTrials.gov Identifier: NCT04011033.

2023-01-01·Frontiers in immunology

CAR-iNKT cells targeting clonal TCRVβ chains as a precise strategy to treat T cell lymphoma.

Article

作者: Ponnusamy, Kanagaraju ; Rowan, Aileen G ; Taylor, Graham P ; Karadimitris, Anastasios ; Ren, Hongwei ; Cook, Lucy B M

Introduction:

Most T cell receptor (TCR)Vβ chain-expressing T cell lymphomas (TCL) including those caused by Human T cell leukaemia virus type-1 (HTLV-1) have poor prognosis. We hypothesised that chimeric antigen receptor (CAR)-mediated targeting of the clonal, lymphoma-associated TCRβ chains would comprise an effective cell therapy for TCL that would minimally impact the physiological TCR repertoire.

Methods:

As proof of concept, we generated CAR constructs to target four TCRVβ subunits. Efficacy of the CAR constructs was tested using conventional T cells as effectors (CAR-T). Since invariant NKT (iNKT) cell do not incite acute graft-versus-host disease and are suitable for 'off-the-shelf' immunotherapy, we generated anti-TCRVβ CAR-iNKT cells.

Results:

We show that anti-TCRVβ CAR-T cells selectively kill their cognate tumour targets while leaving >90% of the physiological TCR repertoire intact. CAR-iNKT cells inhibited the growth of TCL in vivo, and were also selectively active against malignant cells from Adult T cell leukaemia/lymphoma patients without activating expression of HTLV-1.

Discussion:

Thus we provide proof-of-concept for effective and selective anti-TCRVβ CAR-T and -iNKT cell-based therapy of TCL with the latter providing the option for 'off-the-shelf' immunotherapy.

项与 AgenT-797 相关的新闻（医药）

2024-05-22

·GlobeNewswire-Health Care

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced presentation of clinical data on agenT-797 in a complex case of severe acute respiratory distress (ARDS) at the American Thoracic Society (ATS) Annual Meeting. These translational and mechanistic insights build on an expanding dataset of clinical activity for patients with severe ARDS. “Consistent with our prior publication of the survival benefit of agenT-797 in severe respiratory distress, the observed improvement in this case further demonstrates the potential of allogeneic iNKT cells in this setting,” said Dr. Terese Hammond, University of California Los Angeles. “New therapeutic options, like allogeneic cell therapies, are urgently needed to address the critical unmet need in immune-compromised individuals with respiratory distress. I believe this growing body of data illuminates how iNKTs may have an impactful role in treating acute critical illness and merits further investigation.” Clinical Findings Patient: A 26-year-old chronically immunosuppressed patient post-renal transplant contracted COVID-19 and progressed to severe hypoxemic respiratory failure, requiring veno-venous extracorporeal membrane oxygenation (VV-ECMO).Treatment: A single dose of 1x10^9 allogeneic iNKT cells (agenT-797) on hospital day 13.Outcomes: Clinical changes showed a rapid decrease in inflammatory cytokines, including IL-18 following agenT-797 administration, consistent with the data observed in the Phase 1 trial of agenT-797 in COVID-19 ARDS (Hammond, T.C., Nat Commun 2024). The patient was extubated on day 37 and discharged home from the hospital on day 60, weaned off hemodialysis and returned to normal activities of daily living (ADLs) within 6 months of dosing. The full poster presentation can be found on the Publications page of the MiNK website at https://minktherapeutics.com/publications/. About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels. Forward Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic and curative potential of agenT-797 and iNKT cells the mechanism of action, potency and safety, interim or top-line data, including statements regarding clinical data of agenT-797, the anticipated benefits of agenT-797 and clinical development plans and timelines. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Investor Contact 917-362-1370 investor@minktherapeutics.com Media Contact 781-674-4428 communications@minktherapeutics.com

细胞疗法临床结果临床1期免疫疗法AACR会议

2024-05-14

·BioSpace

MiNK Reports First Quarter 2024 Results

Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American Thoracic Society (ATS) AACR presentation reported MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the first quarter 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. “This quarter we made significant strides across our iNKT cell programs, as we remain focused on generating clinical data from our lead program, agenT-797, strengthening our financial position, and advancing our innovative next-generation therapies,” said Dr. Jennifer Buell, Chief Executive Officer, and President of MiNK. “The $5.8 million capital infusion will enable us to accelerate the advancement of MiNK-215 into the clinic, which we believe has exciting potential to address significant unmet needs in solid tumor cancers, as demonstrated by the pre-clinical data we recently presented at AACR.” Business Updates: MiNK successfully closed a private placement financing (PIPE) agreement, raising $5.8 million with a new investor. The proceeds will accelerate the clinical entry of MiNK-215, an investigational IL-15 armored fibroblast activation protein (FAP)-targeting CAR-iNKT cell therapy, currently in IND enabling studies with a filing planned for 2025. Yekaterina ("Katie") Chudnovsky, an accomplished attorney, venture investor, and dedicated patient advocate, has been appointed as a Board Observer at MiNK. Clinical Program Updates: AgenT-797 in Gastroesophageal Cancers: Phase 2 investigator-sponsored trial, led by Dr. Yelena Janjigian at Memorial Sloan Kettering Cancer Center, has been actively enrolling since February 2024. The trial assesses the combination of agenT-797 with Agenus' botensilimab, balstilimab, and standard of care chemotherapy with initial results expected later this year (NCT06251973). ATS Annual Meeting Presentation: A poster presentation at the upcoming ATS Annual Meeting on May 21, 2024, will highlight the clinical efficacy of agenT-797 in treating respiratory distress, particularly focusing on a complex case involving severe COVID-19 complications in a renal transplant patient. Abstract Title: Persistent SARS-CoV-2 Viremia, COVID-19 Associated Acute Respiratory Distress Syndrome, Severe Coagulopathy and Massive Hemoptysis in a Renal Transplant Patient on Veno-Venous Extracorporeal Membrane Oxygenation Abstract Number: P439 Date and Time: May 21, 2024, 11:30 a.m. – 1:15 p.m. PST MiNK-215 Development: Data presented at the AACR Annual Meeting in April 2024, presented robust preclinical data showing MiNK-215’s effectiveness against MSS colorectal cancer liver metastases. The therapy demonstrated significant tumor elimination capabilities through immune activation, tumor stroma remodeling, and enhanced tumor killing. Plans are in place to fast-track the IND filing to early 2025. Financial Results We ended the quarter with a cash balance of $5.8 million. Cash used in operations for the three months ended March 31, 2024 was $2.5 million compared to $4.4 million for the same period in 2023. Net loss for the first quarter of 2024 was $3.8 million, or $0.11 per share, compared to $5.7 million, or $0.17 per share, for the first quarter of 2023. Summary Consolidated Financial Information Condensed Consolidated Balance Sheet Data (in thousands) (unaudited) March 31, 2024 December 31, 2023 Cash and cash equivalents $ 5,817 $ 3,367 Total assets 6,894 4,552 Other Financial Information (in thousands) (unaudited) Three months ended March 31, 2024 2023 Cash used in operations $ 2,542 $ 4,366 Non-cash expenses 650 967 Condensed Consolidated Statements of Operations Data (in thousands, except per share data) (unaudited) Three months ended March 31, 2024 2023 Operating expenses: Research and development 2,550 4,194 General and administrative 1,280 1,660 Operating loss 3,830 5,854 Other income, net (17 ) (168 ) Net loss $ 3,813 $ 5,686 Per common share data, basic and diluted: Net loss $ (0.11 ) $ (0.17 ) Weighted average number of common shares outstanding, basic and diluted 34,643 33,967 Conference Call Dial-in numbers: 646-307-1963 (U.S. – NY), 800-715-9871 (U.S. & Canada) Conference ID: 7888464 Webcast A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at and via . About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels. Forward Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic and curative potential of agenT-797, MiNK-215, and iNKT cells the mechanism of action, potency and safety, interim or top-line data, including statements regarding clinical data of agenT-797 alone and in combination with anti-PD-1, the anticipated benefits of agenT-797 and clinical development plans and timelines. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Investor Contact 917-362-1370 investor@minktherapeutics.com Media Contact 781-674-4428 communications@minktherapeutics.com

细胞疗法财报AACR会议临床2期

2024-03-21

·GlobeNewswire-Health Care

MiNK Reports Fourth Quarter and Year-End 2023 Results

Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced collaboration with Immunoscape for development of TCR-based therapiesPublished clinical data in Nature Communications and Oncogene demonstrating clinical activity of allo-iNKTs, agenT-797, in solid tumors and severe acute respiratory distress NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the fourth quarter and full-year 2023. MiNK executives will host a conference call and webcast at 8:30 a.m. ET to discuss the results and to provide a corporate update. “In 2023, MiNK made significant strides in advancing our allogeneic iNKT cell programs, contributing to a growing body of clinical data that underscores the unique advantages of iNKTs and their pivotal role in immunity,” said Dr. Jennifer Buell, Chief Executive Officer and President at MiNK. “We expanded the scope of our pipeline, solidifying key partnerships such as our research agreement with ImmunoScape. As we move forward, our primary focus remains on advancing our lead program, agenT-797, particularly in indications where we have observed promising proof-of-concept data. We are pleased to announce the progression of this program into a Phase 2 study in gastroesophageal cancers and we anticipate sharing initial trial data later this year.” 2023 Highlights AgenT-797 in Solid Tumors Announced the launch of a Phase 2 investigator-sponsored trial in gastroesophageal cancers, led by Dr. Yelena Janjigian, Chief of Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center (NCT06251973).Supported by Stand Up To Cancer, this trial is actively enrolling and evaluating the combination of agenT-797 (allo-iNKTs), Agenus' botensilimab (a novel Fc-enhanced CTLA-4 inhibitor), along with balstilimab (anti-PD-1), ramucirumab, and paclitaxel.These data aim to provide invaluable insights into the clinical activity and development pathway for this difficult disease, where there are currently no curative therapies available. AgenT-797 in Acute Respiratory Distress (ARDS) MiNK's Phase 1/2 study in patients with moderate to severe ARDS was published in Nature Communications. The study reports survival rates exceeding 70% among patients on mechanical ventilation and surpassing 80% among those receiving VV ECMO support. These results stand in stark contrast to the 10% survival rate observed in the in-hospital control during the same period.Moreover, demonstrating its immunologic properties, agenT-797 showcased a significant reduction in secondary bacterial and fungal infections, with an over 80% decrease in pneumonia cases within the highest dose cohort.Looking ahead, MiNK remains committed to addressing critical unmet needs in respiratory care. The company is poised to advance agenT-797 in patients with viral ARDS through a predominantly externally funded, large platform trial. Research Programs MiNK entered into a collaboration agreement with Immunoscape, aimed to accelerate the development of TCR-based therapies against novel targets in T cells, iNKT cells, and other modalities for solid tumor cancers.MiNK-215 preclinical efficacy was presented at the American Society of Gene and Cell Therapy (ASGCT) 2023 annual meeting that showed MiNK-215’s activity in non-small cell lung cancer (NSCLC) models.MiNK-215 IND enabling activities are underway to support clinical advancement; supportive financing discussions are underway. Manufacturing Progress MiNK continued internal manufacturing of its allogeneic iNKT cells, through an FDA cleared, automated and closed-system process. MiNK is supplying product for its ongoing clinical trials. Financial Results We ended the year with a cash balance of $3.4 million. Since year-end we received $5 million under our convertible note agreement with Agenus Inc. Cash used in operations for the three and twelve months ended December 31, 2023, was $3.0 million, and $15.8 million, respectively, compared to $4.4 million and $18.9 million for the same periods in 2022. Net loss for the year ended December 31, 2023 was $22.5 million, or $0.65 per share, compared to net loss for the same period in 2022 of $28 million or $0.83 per share. Summary Consolidated Financial Information Condensed Consolidated Balance Sheet Data (in thousands) (unaudited) December 31, 2023 2022 Cash and cash equivalents$3,367 $19,636 Total assets 4,552 21,472 Total stockholders' equity (deficit) (18,055) (401) Other Financial Information (in thousands) (unaudited) Three months ended December 31, Year ended December 31, 2023 2022 2023 2022 Cash used in operations$3,025 $4,431 $15,752 $18,867 Non-cash expenses 1,167 706 3,810 358 Condensed Consolidated Statements of Operations Data (in thousands, except per share data) (unaudited) Three months ended December 31, Year ended December 31, 2023 2022 2023 2022 Operating expenses: Research and development 3,311 5,812 15,490 23,115 General and administrative 2,189 2,077 7,431 7,834 Operating loss 5,500 7,889 22,921 30,949 Other expense (income), net (41) (120) (463) (2,958) Net loss$5,459 $7,769 $22,458 $27,991 Per common share data, basic and diluted: Net loss$0.16 $0.23 $0.65 $0.83 Weighted average number of common shares outstanding, basic and diluted 34,558 33,806 34,360 33,673 Conference Call Dial in numbers: 646 - 307-1963 (U.S. – NY), 800-715-9871 (U.S. & Canada) Conference ID: 1391457 Webcast A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/xa2m5uy7. About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels. Forward Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic and curative potential of agenT-797, MiNK-215, and iNKT cells the mechanism of action, potency and safety, interim or top-line data, including statements regarding clinical data of agenT-797 alone and in combination with anti-PD-1, the anticipated benefits of agenT-797 and clinical development plans and timelines. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Investor Contact917-362-1370investor@minktherapeutics.com Media Contact781-674-4428communications@minktherapeutics.com

临床2期细胞疗法财报ASH会议临床结果

100 项与 AgenT-797 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
食管腺癌	临床2期	美国	Memorial Sloan Kettering Cancer Center	2024-02-01
胃食管交界处癌	临床2期	美国	Memorial Sloan Kettering Cancer Center	2024-02-01
转移性食管癌	临床2期	美国	Memorial Sloan Kettering Cancer Center	2024-02-01
转移性胃腺癌	临床2期	美国	Memorial Sloan Kettering Cancer Center	2024-02-01
转移性胃癌	临床2期	美国	Memorial Sloan Kettering Cancer Center	2024-02-01
转移性胃食管结合部腺癌	临床2期	美国	Memorial Sloan Kettering Cancer Center	2024-02-01
新型冠状病毒感染	临床2期	美国	MiNK Therapeutics, Inc.	2020-09-21
呼吸困难	临床2期	美国	MiNK Therapeutics, Inc.	2020-09-21
流感病毒感染	临床2期	美国	MiNK Therapeutics, Inc.	2020-09-21
成人呼吸窘迫综合征	临床2期	美国	MiNK Therapeutics, Inc.	2020-09-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04582201 (Literature) 人工标引	临床1/2期	成人呼吸窘迫综合征	21	agenT-797	顧鑰觸願鏇製餘構鬱範(築廠艱餘窪糧壓齋壓製) = 衊艱憲鏇鏇簾遞繭願襯遞襯窪獵廠顧觸構糧襯 (廠網鹹壓壓築顧範餘廠 )	积极	2024-02-06
NCT05108623 (Literature) 人工标引	临床1期	胃癌	1	AgenT-797	醖廠願積觸廠蓋鏇齋積(鹹積壓衊艱簾構範夢齋) = 簾簾廠膚膚簾襯餘鹽夢蓋醖選襯淵繭廠鹽築醖 (繭觸糧製繭簾壓範襯願 )	积极	2024-01-29
AACR2023 人工标引	临床1期	HR阳性/HER2低表达实体瘤	32	-	網觸醖繭襯窪壓選選製(淵糧網壓遞夢鹹願蓋廠) = 醖範糧網繭網憲獵選艱網鏇膚鑰獵廠鑰憲鏇繭 (夢選鹽觸衊鏇壓網獵鑰 )	积极	2023-04-14
AACR2023 人工标引	临床1期	HR阳性/HER2低表达实体瘤	32	-	鹽蓋憲艱糧製範築醖艱(夢觸觸齋窪選憲鹽廠憲) = 顧鑰鑰衊獵鏇艱餘夢鬱鏇遞顧窪鏇願範製衊壓 (淵鹽製襯鹽製鏇窪夢製 )	积极	2023-04-14